Vagomimetic effects of fingolimod: Physiology and clinical implications

CNS Neuroscience and Therapeutics

Volumn 20, Issue 6, 2014, Pages 496-502

  Vanoli, Emilio ^a,b   Pentimalli, Francesco ^c   Botto, Gianluca ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c SANT ANNA HOSPITAL   (Italy)

Author keywords

Atrioventricular block; Bradycardia; Cardiac electrophysiology; Fingolimod

Indexed keywords

ATROPINE; FINGOLIMOD; GUANINE NUCLEOTIDE BINDING PROTEIN; RISPERIDONE; SPHINGOSINE 1 PHOSPHATE; IMMUNOSUPPRESSIVE AGENT; LYSOPHOSPHOLIPID; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE;

BRADYCARDIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPLETE HEART BLOCK; DOSE RESPONSE; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; EVENT FREE SURVIVAL; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART MUSCLE CONDUCTION SYSTEM; HEART PACING; HUMAN; ISCHEMIC HEART DISEASE; MULTIPLE SCLEROSIS; P WAVE; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); QRS COMPLEX; REVIEW; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SINUS BRADYCARDIA; SINUS NODE DISEASE; SLEEP DISORDERED BREATHING; VAGUS NERVE STIMULATION; ANALOGS AND DERIVATIVES; ANIMAL; ATRIOVENTRICULAR BLOCK; CHEMICALLY INDUCED; ELECTROCARDIOGRAPHY; METABOLISM; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ANIMALS; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; ELECTROCARDIOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYSOPHOSPHOLIPIDS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84900503531     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12283     Document Type: Review

References (76)

1. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-897.
2. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
3. DiMarco JP, O'Conner P, Cohen JA, et al. Fingolimod treatment initiation experience: Cardiac and Holter electrocardiogram findings from three phase 3 studies. Mult Scler 2012;18:227.
4. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
5. Cohen JA, O'Conner P, Caliolio T, et al. Long term safety of fingolimod in relapsing multiple sclerosis: Update to integrated analyses of phase 2 and 3 studies and extension phases. Mult Scler 2012;18:454.
6. Novartis Pharma. Summary of Product Characteristics - Gilenya 0.5 mg. Available at:http://www.medicines.org.uk/EMC/medicine/24443/SPC/Gilenya+0.5mg+hard+capsules/. Last updated 2 May 2013. Accessed 9 August 2013.
7. Novartis Pharma. Prescribing Information - GILENYA (fingolimod) capsules. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf. Last updated 5 September 2012. Accessed 9 August 2013.
8. Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6:373-382.
9. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101.
10. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005;5:529-536.
11. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115:84-105.
12. Kurachi Y. G protein regulation of cardiac muscarinic potassium channel. Am J Physiol 1995;269:C821-C830.
13. Gold R, Comi G, Palace J, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study. J Neurol 2014;261:267-276.
14. Hughes BL, Cascione M, McCague K, et al. Cardiac effects of fingolimod after first dose administration and therapy change in patients with multiple sclerosis. Neurology 2013;80:P01.170.
15. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices). Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-e62.
16. Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J 2007;28:2256-2295.
17. Brodsky M, Wu D, Denes P, Kanakis C, Rosen KM. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977;39:390-395.
18. Scott O, Williams GJ, Fiddler GI. Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years. Br Heart J 1980;44:304-308.
19. Dickinson DF, Scott O. Ambulatory electrocardiographic monitoring in 100 healthy teenage boys. Br Heart J 1984;51:179-183.
20. Southall DP, Johnston F, Shinebourne EA, Johnston PG. 24-hour electrocardiographic study of heart rate and rhythm patterns in population of healthy children. Br Heart J 1981;45:281-291.
21. Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: Detection by 24-hour ambulatory electrocardiography. Chest 1982;81:302-307.
22. Viitasalo MT, Kala R, Eisalo A. Ambulatory electrocardiographic recording in endurance athletes. Br Heart J 1982;47:213-220.
23. Crouse SF, Meade T, Hansen BE, Green JS, Martin SE. Electrocardiograms of collegiate football athletes. Clin Cardiol 2009;32:37-42.
24. Rubart M, Zipes DP. Arrhythmias, sudden death and syncope. In: Libby P, Bonow RO, Mann DL, Zipes D, editors. Braunwald's heart disease. Philadelphia, PA: Saunders Elsevier, 2008;909-921.
25. Bharati S, Goldschlager N, Kusumoto F, et al. Sinus node dysfunction. In: Camm AJ, Saksena S, editors. Electrophysiological disorders of the heart. Philadelphia, PA: Elsevier Churchill-Livingston, 2005;207-226.
26. Haverkamp W, Breithardt G. Therapie bradykarder rhythmusstörungen. In: Moderne herzrhythmustherapie. Stuttgart: Thieme, 2003;145-170.
27. Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N Engl J Med 2000;342:703-709.
28. Monfredi O, Dobrzynski H, Mondal T, Boyett MR, Morris GM. The anatomy and physiology of the sinoatrial node-a contemporary review. Pacing Clin Electrophysiol 2010;33:1392-1406.
29. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol 2004;44:109-116.
30. Spodick DH, Raju P, Bishop RL, Rifkin RD. Operational definition of normal sinus heart rate. Am J Cardiol 1992;69:1245-1246.
31. Stegman SS, Burroughs JM, Henthorn RW. Asymptomatic bradyarrhythmias as a marker for sleep apnea: Appropriate recognition and treatment may reduce the need for pacemaker therapy. Pacing Clin Electrophysiol 1996;19:899-904.
32. Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am J Cardiol 1983;52:490-494.
33. Holden W, McAnulty JH, Rahimtoola SH. Characterisation of heart rate response to exercise in the sick sinus syndrome. Br Heart J 1978;40:923-930.
34. Goldschlager N, Saksena S, Bharati S, et al. Atrioventricular block. In: Saksena S, Camm A, editors. Electrophysiological disorders of the heart. Philadelphia, PA: Elsevier Churchill-Livingston, 2005;229-247.
35. Bhat PK, Watanabe K, Rao DB, Luisada AA. Conduction defects in the aging heart. J Am Geriatr Soc 1974;22:517-520.
36. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: Calendar year 2009-a World Society of Arrhythmia's project. Pacing Clin Electrophysiol 2011;34:1013-1027.
37. Schwartzmann D. Atrioventricular block and atrioventricular dissociation. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: From cell to bedside, 4th edn. Philadelphia, PA: Saunders, 2004;485-489.
38. Sekhri V, Sanal S, Delorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: A comprehensive review. Arch Med Sci 2011;7:546-554.
39. Chiba Y, Oka K, Saito H, Nagayama R, Murata M, Mori N. Primary cardiac B-cell lymphoma presented as heart tamponade and atrioventricular block: A case report. Acta Cytol 2010;54:79-81.
40. Vallés V, Malpartida F, Alegría E, et al. Complete heart block and post-radiotherapy constrictive pericarditis. A proposal of a case. Rev Med Univ Navarra 1981;25:21-23.
41. Pelargonio G, Fogel RI, Knilans TK, Prystowsky EN. Late occurrence of heart block after radiofrequency catheter ablation of the septal region: Clinical follow-up and outcome. J Cardiovasc Electrophysiol 2001;12:56-60.
42. Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: Final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation 1999;99:262-270.
43. Lenegre J. Etiology and pathology of bilateral bundle branch block in relation to complete heart block. Prog Cardiovasc Dis 1964;6:409-444.
44. Lev M. The pathology of complete atrioventricular block. Prog Cardiovasc Dis 1964;6:317-326.
45. Chokshi SK, Sarmiento J, Nazari J, Mattioni T, Zheutlin T, Kehoe R. Exercise-provoked distal atrioventricular block. Am J Cardiol 1990;66:114-116.
46. Barold SS, Ilercil A, Leonelli F, Herweg B. First-degree atrioventricular block. Clinical manifestations, indications for pacing, pacemaker management & consequences during cardiac resynchronization. J Interv Card Electrophysiol 2006;17:139-152.
47. Mymin D, Mathewson FA, Tate RB, Manfreda J. The natural history of primary first-degree atrioventricular heart block. N Engl J Med 1986;315:1183-1187.
48. Issa Z, Miller JM, Zipes DP. Atrioventricular conduction abnormalities: A companion to Braunwald's heart disease. In: Clinical arrhythmology and electrophysiology. Philadelphia, PA: Saunders, 2008;127-142.
49. Strasberg B, Amat-Y-Leon F, Dhingra RC, et al. Natural history of chronic second-degree atrioventricular nodal block. Circulation 1981;63:1043-1049.
50. Shaw DB, Kekwick CA, Veale D, Gowers J, Whistance T. Survival in second degree atrioventricular block. Br Heart J 1985;53:587-593.
51. Shaw DB, Gowers JI, Kekwick CA, New KH, Whistance AW. Is Mobitz type I atrioventricular block benign in adults? Heart 2004;90:169-174.
52. Dhingra RC, Denes P, Wu D, Chuquimia R, Rosen KM. The significance of second degree atrioventricular block and bundle branch block. Observations regarding site and type of block. Circulation 1974;49:638-646.
53. Vogler J, Breithardt G, Eckardt L. Bradyarrhythmias and conduction blocks. Rev Esp Cardiol (Engl Ed) 2012;65:656-667.
54. Sykes JA, Lubega J, Ezetendu C, Verma R, O'Connor B, Kalyanaraman M. Asymptomatic complete atrioventricular block in a 13-year-old girl. Pediatr Emerg Care 2011;27:1081-1083.
55. Alboni P, Gianfranchi L, Brignole M. Treatment of persistent sinus bradycardia with intermittent symptoms: Are guidelines clear? Europace 2009;11:562-564.
56. Brubaker PH, Kitzman DW. Chronotropic incompetence: Causes, consequences, and management. Circulation 2011;123:1010-1020.
57. DiMarco JP, Philbrick JT. Use of ambulatory electrocardiographic (Holter) monitoring. Ann Intern Med 1990;113:53-68.
58. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol 1999;34:912-948.
59. Brignole M, Vardas P, Hoffman E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 2009;11:671-687.
60. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999;341:1351-1357.
61. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992;85:I77-I91.
62. Vanoli E, Cerati D, Pedretti RFE. Autonomic control of heart rate: Pharmacological and nonpharmacological modulation. In: Hasenfuss G, Just H, editors. Heart rate as a determinant of a cardiac function - basic mechanism and clinical significance. Darmstadt: Steinkopff, Springer, 2000;215-229.
63. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 1991;68:1471-1481.
64. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478-484.
65. Myers RW, Pearlman AS, Hyman RM, et al. Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia. Circulation 1974;49:943-947.
66. Kent KM, Smith ER, Redwood DR, Epstein SE. Electrical stability of acutely ischemic myocardium. Influences of heart rate and vagal stimulation. Circulation 1973;47:291-298.
67. Sabbah HN, Zaca V, Wang M, et al. 53 Cardiac contractility modulation electrical signals improve LV diastolic function in dogs with heart failure. Eur J Heart Fail 2007;6(Suppl):8, abstract 53.
68. Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2009;2:692-699.
69. De Ferrari GM, Crijns HJ, Borggrefe M, et al. Chronic vagus nerve stimulation: A new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011;32:847-855.
70. Ben-Menachem E. Vagus nerve stimulation, side effects, and long-term safety. J Clin Neurophysiol 2001;18:415-418.
71. Schachter SC. Vagus nerve stimulation therapy summary: Five years after FDA approval. Neurology 2002;59:S15-S20.
72. Shuchman M. Approving the vagus-nerve stimulator for depression. N Engl J Med 2007;356:1604-1607.
73. Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med 1988;319:1379-1384.
74. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993;328:533-537.
75. Faber H, Fischer HJ, Weber F. Prolonged and symptomatic bradycardia following a single dose of fingolimod. Mult Scler 2013;19:126-128.
76. Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult Scler 2011;17:1387-1389.